Generics - USA

Filter

Current filters:

USA

Popular Filters

51 to 75 of 137 results

Hospira’s Retacrit effective in chemotherapy-induced anemia

Hospira’s Retacrit effective in chemotherapy-induced anemia

24-07-2014

USA-based Hospira, a leading provider of generic injectable drugs and infusion technologies, announced…

BiosimilarsErythropoiesis-stimulating agentsGenericsHematologyHospiraInfusion technologiesResearchRetacritUSA

Hikma to take over Boehringer’s Ben Venue manufacturing site

24-07-2014

Jordan-based drugmaker Hikma Pharmaceuticals says it has agreed with Ben Venue Laboratories, part of…

Ben Venue LabsBoehringer IngelheimGenericsHikma PharmaceuticalsMergers & AcquisitionsProductionUSA

Mylan wins motion to enjoin GSK from providing paroxetine CR to Apotex

Mylan wins motion to enjoin GSK from providing paroxetine CR to Apotex

17-07-2014

US generics drug major Mylan says that the US District Court for the District of New Jersey granted its…

ApotexGenericsGlaxoSmithKlineLegalMylanNeurologicalparoxetinePaxil-CRUSA

Glenmark Pharma to set up new manufacturing facility in USA

Glenmark Pharma to set up new manufacturing facility in USA

17-07-2014

Indian drugmaker Glenmark Pharmaceuticals plans to set up a new manufacturing facility at Monroe Corporate…

GenericsGlenmark PharmaceuticalsProductionUSA

Impax Labs receives subpoena over digoxin

Impax Labs receives subpoena over digoxin

16-07-2014

US generic drugmaker Impax Laboratories revealed in a Securities Exchange Commission filing that, on…

Cardio-vascularCardiologydigoxinGenericsImpax LaboratoriesLegalMarkets & MarketingUSA

FDA accepts Teva’s NDA for albuterol MDPI

FDA accepts Teva’s NDA for albuterol MDPI

15-07-2014

Israel-based generic giant Teva Pharmaceuticals Industries says that the US Food and Drug Administration…

albuterolExercise-induced bronchospasmGenericsPulmonologyRegulationRespiratory and PulmonaryTeva Pharmaceutical IndustriesUSA

US regulatory warnings on drug producers extend well beyond India

US regulatory warnings on drug producers extend well beyond India

14-07-2014

Hauled up by the US Food and Drug Administration for product recalls and quality issues, Indian pharmaceutical…

CiplaDr Reddy's LaboratoriesGenericsIndiaLupinProductionRanbaxy LaboratoriesRegulationSun PharmaceuticalUSA

Actavis confirms patent challenge to Duchesnay’s Diclegis

Actavis confirms patent challenge to Duchesnay’s Diclegis

12-07-2014

Ireland-based generics major Actavis on Friday confirmed that it has filed an Abbreviated New Drug Application…

ActavisDiclegisDuchesnayGenericsPatentsRegulationUSAWomen's Health

Acorda fights Actavis on generic of its multiple sclerosis drug Ampyra

Acorda fights Actavis on generic of its multiple sclerosis drug Ampyra

09-07-2014

Ireland-headquartered generics major Actavis has confirmed filing an Abbreviated New Drug Application…

Acorda TherapeuticsActavisAmpyradalfampridineGenericsLegalNeurologicalUSA

Mylan launches generic Micardis in USA

Mylan launches generic Micardis in USA

08-07-2014

US generic drugmaker Mylan has launched Telmisartan Tablets USP, 20mg, 40mg and 80mg, the generic version…

Boehringer IngelheimCardio-vascularGenericsMarkets & MarketingMicardisMylanRegulationTelmisartanUSA

Indian generics sector hires India First Group to re-establish its reputation

Indian generics sector hires India First Group to re-establish its reputation

01-07-2014

USA-based generic drugmakers want high quality, low cost generic pharmaceuticals made in India and the…

GenericsHealthcareIndiaPricingUSA

FTC approves final order on Akorn’s acquisition of Hi-Tech

FTC approves final order on Akorn’s acquisition of Hi-Tech

22-06-2014

Following a public comment period, the US Federal Trade Commission on Friday approved a final order settling…

AkornGenericsHi-Tech PharmacalMergers & AcquisitionsUSAValeant Pharmaceuticals International

FTC amicus brief: Improper use of restricted drug distribution programs may impede generic competition

FTC amicus brief: Improper use of restricted drug distribution programs may impede generic competition

20-06-2014

The US Federal Trade Commission has filed an amicus brief in the New Jersey US District Court explaining…

CelgeneGenericsLegalMylanPharmaceuticalRegulationUSA

Prime Therapeutics' 2013 overall net cost per Rx of $58.99 is industry-low for third consecutive year

Prime Therapeutics' 2013 overall net cost per Rx of $58.99 is industry-low for third consecutive year

17-06-2014

In 2013, US Pharmacy Benefit Manager (PBM) Prime Therapeutic's average net ingredient cost per prescription…

GenericsHealthcarePricingUSA

51 to 75 of 137 results

Back to top